All posts by medical

The Neuroscience Behind Kejriwals Victory – The Wire

Arvind Kejriwals victory is currently being viewed from the perspective of a development centred narrative coupled with a platitude of freebies offered by the Aam Admi Party (AAP). However, if one analyses past election results, voters have rejected pro-development governments on a number of occasions.

The governments of Narasimha Rao, as well as Vajpayee, were decisively rejected by the voters, despite their strong development-centric approaches. Freebies have been also rejected by voters rejection of Congress Nyay scheme during the 2019 elections is a glaring example. What then makes Kejriwal so special that both factors which have pushed many governments into oblivion worked in favour of AAP?

The answer to these questions lies in Neuroscience. We have all read about Pavlovs work on conditioned reflexes based on experiments, where an animal was given food and a bell was rung. After a while, the animal started feeling hungry and began to salivate when the bell was rung. This is also called classical conditioning where, a conditioned stimulus e.g. the sound of a bell, is paired with unconditioned stimulus e.g. food which evokes salivation which is an unconditioned response requiring no training.

After the pairing is repeated, the animal demonstrates a conditioned (or doctored) response to the conditioned stimulus or the external agent. The key observation is that repeated enforcement of a given pattern at the mental level, can actuate specific action patterns. This is exactly, what Kejriwal has done.

Also read: AAP: Soft Hindutva or a Bulwark Without Illusions?

He did not offer a one-time waiver of loans to people, as many other governments have done, as people are not only likely to forget it with time but their aspirations also rise, leading to an increase in anti-incumbency. Kejriwal partially waived off electricity and water bills, which impacted the public periodically while entrenching his image as a family caretaker.

Kejriwal identified two other areas, from which a conditioned response could be evoked within a definite timeframe education and health. He knew that improving the quality of education in government schools was extremely difficult to achieve in the short run, so he focused mainly on building classrooms in schools. Most people tend to cross a site near a school on a daily basis.

The emergence of huge buildings can convince people into believing that the quality of education is changing for the better. It affects parents, wards and the general public on a daily basis. Kejriwal also directed the remaining efforts towards the health sector. He set up Mohalla clinics, which may not offer quality health services, but the thought of someone in ones neighbourhood, to attend to them during distress can be a great mental stimulus for the voters.

Voters queue at a polling booth for the New Delhi assembly election in the Indian capital on February 8, 2020. Photo: Reuters

Kejriwal has always believed in making immediate and short term impact with minimal efforts. His odd-even scheme to control rising air pollution in the city was mostly hype and little substance, but people did talk about it while enhancing his pro-development image. His more recent efforts towards making bus transportation free for women also fall along this direction.

The voters of Delhi have failed to realise that Kejriwals investment in infrastructure-based projects, something which was radically done by the Sheila Dikshit government, has drastically fallen behind. For example, capital expenditure, which is associated with investments in infrastructure, has fallen to 0.54% of GSDP in 2018-19 from 1.16% in 2011-12. Declining tax revenues, which have dropped from 5.49% of GSDP in 2015-16 to 4.93% in 2018-19, are a cause of concern. But then, people tend to get swayed by actions having an immediate impact and this is one of the key pitfalls of democratic process.

Also read: AAP Has Successfully Forged a Model for Regional Forces to Emulate

The BJP government had sufficient time towards initiating a set of efforts directed towards creating a specific pro-development image and associated cognitive states in Delhi. For example, they could have set up dozens of central universities, hospitals and schools for residents, which could have had a cascading effect on peoples psyche.

Instead, the BJP chose to focus on things, which had absolutely very little cognitive value. Sentiment driven elements can also have strong cognitive values, but only when other narratives are absent. A typical middle-class family in Delhi cares little about Article 370, CAA and the Ram Temple. The BJPs rise in vote share is mostly driven by the disenchantment of a class which is fed up with schemes which benefit people and who do not pay direct taxes. It does not imply support for BJPs particular strategies, which would actually have minimal effect in their mental day to day lives.

In the context of Modis return to power, his schemes focusing on the construction of toilets, electricity connection and gas supplies in the rural sector also had a very strong cognitive value. The Balakot strikes galvanised his image as a strong leader, who could take decisive decisions. But in recent times, the impact of these narratives is slowly fading and people need newer and stronger initiatives which could excite favourable cognitive patterns. That has been one of the key reasons behind the BJPs dismal performance in key state elections.

There are significant barriers when it comes to replicating Kejriwals model at the national level. Offering free transport or waiving off electricity bills on a large scale is not economically feasible. Hence, AAP may find it difficult to leverage these successes on a pan India level, as his actions have localised cognitive values, confined to Delhi.

Also read: With Another Win in Delhi, Is Arvind Kejriwal Moving to the National Pulpit?

However, AAP does pose a significant threat as other governments may misread his adventurism in the field of freebies and can create a catastrophic burden on the taxpayer. Despite all these, he has sent a strong lesson to other governments that by focusing on health, education and basic necessities, voters thoughts can be significantly swayed in a specific direction, cutting across caste and religious lines, which carries some hope for the future.

Kejriwal has conditioned the psyche of Delhi in a manner that residents tend to strongly associate water, electricity, transportation, school and healthcare with him, which accounts for his grandiose victory in the heart of Hindi heartland.

Dhiraj Sinha holds a doctorate from the University of Cambridge. He has authored several research papers in the field of systems driven far away from equilibrium.

See the original post:
The Neuroscience Behind Kejriwals Victory - The Wire

Jeremy Shaw explores neuroscience and science fiction in new installation – FACT

Phase Shifting Index is presented as part of the Mutations/Creations series at Center Pompidou.

Berlin-based artist Jeremy Shaw will debut a new solo work at Pariss Center Pompidou this month.

Phase Shifting Index arrives as part of the museums Mutations/Creations program, which previously has seen artists Ross Lovegrove, Ryoji Ikeda and Erika Verzutti showing work that exists at the border of art, science and engineering.

Drawing on Shaws enduring interest in ritual, dance, alternative culture, science-fiction and neuroscience, Phase Shifting Index is a new immersive installation that is a continuation on the themes of his recently completed Quantification Trilogy. Watch Jeremy Shaw talking about one of the films from that trilogy, Liminals, below.

Phase Shifting Index runs from February 26 to April 20 at Gallery 3, Centre Pompidou. Tickets are available now.

Watch next: CTM 2020 in videos Robert Henke, Teto Preto, Kamaal Williams and more

Go here to see the original:
Jeremy Shaw explores neuroscience and science fiction in new installation - FACT

Recording waves, reading minds – Science Magazine

Our brains, each of which thrums with enough electrical energy to power a low-wattage light bulb, can now be measured and explored much better than ever beforea boon for doctors seeking better medical treatments and a thrill for inventors crossing neuroscience thresholds, but a warning, too, as our personalities and thoughts become less private and potentially more exploitable. In Electric Brain, R. Douglas Fields details scientists' quest to understand brain waves throughout history, covering a good deal of unsettling material in the process and touching on today's emerging technology and most pressing ethical questions.

See the original post:
Recording waves, reading minds - Science Magazine

Neuroscience Antibodies and Assays Market Latest Trends, Business Strategies, Regional Demand, Key Insights and Future Outlook by 2023 – Jewish Life…

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Neuroscience Antibodies and Assays Report by Material, Application, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

In this report, the global Neuroscience Antibodies and Assays market is valued at USD XX million in 2020 and is projected to reach USD XX million by the end of 2024, growing at a CAGR of XX% during the period 2020 to 2024.

The report firstly introduced the Neuroscience Antibodies and Assays basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:AbcamBio-Rad LaboratoriesCell Signaling TechnologyRocheMerck KGaATecan GroupThermo Fisher Scientific

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Neuroscience Antibodies and Assays for each application, including-Medical

Table of Contents

Part I Neuroscience Antibodies and Assays Industry Overview

Chapter One Neuroscience Antibodies and Assays Industry Overview1.1 Neuroscience Antibodies and Assays Definition1.2 Neuroscience Antibodies and Assays Classification Analysis1.2.1 Neuroscience Antibodies and Assays Main Classification Analysis1.2.2 Neuroscience Antibodies and Assays Main Classification Share Analysis1.3 Neuroscience Antibodies and Assays Application Analysis1.3.1 Neuroscience Antibodies and Assays Main Application Analysis1.3.2 Neuroscience Antibodies and Assays Main Application Share Analysis1.4 Neuroscience Antibodies and Assays Industry Chain Structure Analysis1.5 Neuroscience Antibodies and Assays Industry Development Overview1.5.1 Neuroscience Antibodies and Assays Product History Development Overview1.5.1 Neuroscience Antibodies and Assays Product Market Development Overview1.6 Neuroscience Antibodies and Assays Global Market Comparison Analysis1.6.1 Neuroscience Antibodies and Assays Global Import Market Analysis1.6.2 Neuroscience Antibodies and Assays Global Export Market Analysis1.6.3 Neuroscience Antibodies and Assays Global Main Region Market Analysis1.6.4 Neuroscience Antibodies and Assays Global Market Comparison Analysis1.6.5 Neuroscience Antibodies and Assays Global Market Development Trend Analysis

Chapter Two Neuroscience Antibodies and Assays Up and Down Stream Industry Analysis2.1 Upstream Raw Materials Analysis2.1.1 Proportion of Manufacturing Cost2.1.2 Manufacturing Cost Structure of Neuroscience Antibodies and Assays Analysis2.2 Down Stream Market Analysis2.2.1 Down Stream Market Analysis2.2.2 Down Stream Demand Analysis2.2.3 Down Stream Market Trend Analysis

Part II Asia Neuroscience Antibodies and Assays Industry (The Report Company Including the Below Listed But Not All)

Chapter Three Asia Neuroscience Antibodies and Assays Market Analysis3.1 Asia Neuroscience Antibodies and Assays Product Development History3.2 Asia Neuroscience Antibodies and Assays Competitive Landscape Analysis3.3 Asia Neuroscience Antibodies and Assays Market Development Trend

Chapter Four 2015-2020 Asia Neuroscience Antibodies and Assays Productions Supply Sales Demand Market Status and Forecast4.1 2015-2020 Neuroscience Antibodies and Assays Production Overview4.2 2015-2020 Neuroscience Antibodies and Assays Production Market Share Analysis4.3 2015-2020 Neuroscience Antibodies and Assays Demand Overview4.4 2015-2020 Neuroscience Antibodies and Assays Supply Demand and Shortage4.5 2015-2020 Neuroscience Antibodies and Assays Import Export Consumption4.6 2015-2020 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Chapter Five Asia Neuroscience Antibodies and Assays Key Manufacturers Analysis5.1 Company A5.1.1 Company Profile5.1.2 Product Picture and Specification5.1.3 Product Application Analysis5.1.4 Capacity Production Price Cost Production Value5.1.5 Contact Information5.2 Company B5.2.1 Company Profile5.2.2 Product Picture and Specification5.2.3 Product Application Analysis5.2.4 Capacity Production Price Cost Production Value5.2.5 Contact Information5.3 Company C5.3.1 Company Profile5.3.2 Product Picture and Specification5.3.3 Product Application Analysis5.3.4 Capacity Production Price Cost Production Value5.3.5 Contact Information5.4 Company D5.4.1 Company Profile5.4.2 Product Picture and Specification5.4.3 Product Application Analysis5.4.4 Capacity Production Price Cost Production Value5.4.5 Contact InformationChapter Six Asia Neuroscience Antibodies and Assays Industry Development Trend6.1 2020-2024 Neuroscience Antibodies and Assays Production Overview6.2 2020-2024 Neuroscience Antibodies and Assays Production Market Share Analysis6.3 2020-2024 Neuroscience Antibodies and Assays Demand Overview6.4 2020-2024 Neuroscience Antibodies and Assays Supply Demand and Shortage6.5 2020-2024 Neuroscience Antibodies and Assays Import Export Consumption6.6 2020-2024 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Part III North American Neuroscience Antibodies and Assays Industry (The Report Company Including the Below Listed But Not All)

Chapter Seven North American Neuroscience Antibodies and Assays Market Analysis7.1 North American Neuroscience Antibodies and Assays Product Development History7.2 North American Neuroscience Antibodies and Assays Competitive Landscape Analysis7.3 North American Neuroscience Antibodies and Assays Market Development Trend

Chapter Eight 2015-2020 North American Neuroscience Antibodies and Assays Productions Supply Sales Demand Market Status and Forecast8.1 2015-2020 Neuroscience Antibodies and Assays Production Overview8.2 2015-2020 Neuroscience Antibodies and Assays Production Market Share Analysis8.3 2015-2020 Neuroscience Antibodies and Assays Demand Overview8.4 2015-2020 Neuroscience Antibodies and Assays Supply Demand and Shortage8.5 2015-2020 Neuroscience Antibodies and Assays Import Export Consumption8.6 2015-2020 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Chapter Nine North American Neuroscience Antibodies and Assays Key Manufacturers Analysis9.1 Company A9.1.1 Company Profile9.1.2 Product Picture and Specification9.1.3 Product Application Analysis9.1.4 Capacity Production Price Cost Production Value9.1.5 Contact Information9.2 Company B9.2.1 Company Profile9.2.2 Product Picture and Specification9.2.3 Product Application Analysis9.2.4 Capacity Production Price Cost Production Value9.2.5 Contact InformationChapter Ten North American Neuroscience Antibodies and Assays Industry Development Trend10.1 2020-2024 Neuroscience Antibodies and Assays Production Overview10.2 2020-2024 Neuroscience Antibodies and Assays Production Market Share Analysis10.3 2020-2024 Neuroscience Antibodies and Assays Demand Overview10.4 2020-2024 Neuroscience Antibodies and Assays Supply Demand and Shortage10.5 2020-2024 Neuroscience Antibodies and Assays Import Export Consumption10.6 2020-2024 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Part IV Europe Neuroscience Antibodies and Assays Industry Analysis (The Report Company Including the Below Listed But Not All)

Chapter Eleven Europe Neuroscience Antibodies and Assays Market Analysis11.1 Europe Neuroscience Antibodies and Assays Product Development History11.2 Europe Neuroscience Antibodies and Assays Competitive Landscape Analysis11.3 Europe Neuroscience Antibodies and Assays Market Development Trend

Chapter Twelve 2015-2020 Europe Neuroscience Antibodies and Assays Productions Supply Sales Demand Market Status and Forecast12.1 2015-2020 Neuroscience Antibodies and Assays Production Overview12.2 2015-2020 Neuroscience Antibodies and Assays Production Market Share Analysis12.3 2015-2020 Neuroscience Antibodies and Assays Demand Overview12.4 2015-2020 Neuroscience Antibodies and Assays Supply Demand and Shortage12.5 2015-2020 Neuroscience Antibodies and Assays Import Export Consumption12.6 2015-2020 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Chapter Thirteen Europe Neuroscience Antibodies and Assays Key Manufacturers Analysis13.1 Company A13.1.1 Company Profile13.1.2 Product Picture and Specification13.1.3 Product Application Analysis13.1.4 Capacity Production Price Cost Production Value13.1.5 Contact Information13.2 Company B13.2.1 Company Profile13.2.2 Product Picture and Specification13.2.3 Product Application Analysis13.2.4 Capacity Production Price Cost Production Value13.2.5 Contact InformationChapter Fourteen Europe Neuroscience Antibodies and Assays Industry Development Trend14.1 2020-2024 Neuroscience Antibodies and Assays Production Overview14.2 2020-2024 Neuroscience Antibodies and Assays Production Market Share Analysis14.3 2020-2024 Neuroscience Antibodies and Assays Demand Overview14.4 2020-2024 Neuroscience Antibodies and Assays Supply Demand and Shortage14.5 2020-2024 Neuroscience Antibodies and Assays Import Export Consumption14.6 2020-2024 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Part V Neuroscience Antibodies and Assays Marketing Channels and Investment Feasibility

Chapter Fifteen Neuroscience Antibodies and Assays Marketing Channels Development Proposals Analysis15.1 Neuroscience Antibodies and Assays Marketing Channels Status15.2 Neuroscience Antibodies and Assays Marketing Channels Characteristic15.3 Neuroscience Antibodies and Assays Marketing Channels Development Trend15.2 New Firms Enter Market Strategy15.3 New Project Investment Proposals

Chapter Sixteen Development Environmental Analysis16.1 China Macroeconomic Environment Analysis16.2 European Economic Environmental Analysis16.3 United States Economic Environmental Analysis16.4 Japan Economic Environmental Analysis16.5 Global Economic Environmental Analysis

Chapter Seventeen Neuroscience Antibodies and Assays New Project Investment Feasibility Analysis17.1 Neuroscience Antibodies and Assays Market Analysis17.2 Neuroscience Antibodies and Assays Project SWOT Analysis17.3 Neuroscience Antibodies and Assays New Project Investment Feasibility Analysis

Part VI Global Neuroscience Antibodies and Assays Industry Conclusions

Chapter Eighteen 2015-2020 Global Neuroscience Antibodies and Assays Productions Supply Sales Demand Market Status and Forecast18.1 2015-2020 Neuroscience Antibodies and Assays Production Overview18.2 2015-2020 Neuroscience Antibodies and Assays Production Market Share Analysis18.3 2015-2020 Neuroscience Antibodies and Assays Demand Overview18.4 2015-2020 Neuroscience Antibodies and Assays Supply Demand and Shortage18.5 2015-2020 Neuroscience Antibodies and Assays Import Export Consumption18.6 2015-2020 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Chapter Nineteen Global Neuroscience Antibodies and Assays Industry Development Trend19.1 2020-2024 Neuroscience Antibodies and Assays Production Overview19.2 2020-2024 Neuroscience Antibodies and Assays Production Market Share Analysis19.3 2020-2024 Neuroscience Antibodies and Assays Demand Overview19.4 2020-2024 Neuroscience Antibodies and Assays Supply Demand and Shortage19.5 2020-2024 Neuroscience Antibodies and Assays Import Export Consumption19.6 2020-2024 Neuroscience Antibodies and Assays Cost Price Production Value Gross Margin

Chapter Twenty Global Neuroscience Antibodies and Assays Industry Research Conclusions

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Go here to see the original:
Neuroscience Antibodies and Assays Market Latest Trends, Business Strategies, Regional Demand, Key Insights and Future Outlook by 2023 - Jewish Life...

She overcame 6 brain surgeries and exchanged her hospital gown for scrubs: ‘It’s my destiny’ – wtvr.com

RICHMOND, Va. During her childhood, Alexa Nixon was more familiar with surgeons than swing sets and spent more time in the pediatric unit than the playground.

I was filled with hope, but I dont look hopeful, said Alexa.

When she was 11, she was wracked by seizures. An MRI revealed a brain tumor the size of a ping pong ball. She had her first surgery in 2005. It would be the first of six brain surgeries.

Waking up out of surgery I couldnt move my left side at all, Alexa recalled. It was also told to me that the likelihood of me walking was small if not none. Then in 2012, I got to the point where I was having on average 10 to 12 seizures a day.

During her long recovery, caregivers left a deep impression on Alexa.

I was very intrigued, and I asked a lot of questions to the nurses that took care of me because I realized this is something, I might want to do one day, she said.

So, Alexa set a goal.

When we first met Alexa in 2016, she was working toward her degree in nursing. You would understand if Alexa wanted nothing to do with hospitals. Today, it's where the 26-year-old feels most comfortable.

I know where I am is where Im supposed to be, said Alexa.

Alexa works in the Acute Neuroscience Unit at VCU Medical Center as a nurse. It is the same unit where she spent so much time as a child.

Its my destiny. And every day I get to live out my destiny, said Alexa.

Alexa sees herself in the faces of the patients she cares for.

Sometimes it hits too close to home, but it makes me that much more driven, said Alexa.

She credits her faith, family and friends with helping her recover and reach her goal.

Every morning when I come to work, I know Im coming to work to do Gods work, she said.

Fellow nurses Jillian Phillips and Morgan Knowles say their colleague possesses intangibles you just can't learn in a classroom.

Oh, Definitely. Yeah. She was definitely made to be a nurse and be there for other people, said Morgan.

She is what you would imagine as the most trusted profession. What people look to as a nurse that is Alexa, added Jillian.

Alexa is setting out on her calling rather than a career.

If in some freak way that Nursing was not a paid profession it would be my hobby, said Alexa.

Alexa Nixon, a one-time patient realizing her dream of helping others all while exchanging her hospital gown for scrubs.

I obviously want to grow as a nurse and in leadership, but I never want to leave the bedside because the patient relationship is why Im here, said Alexa.

Greg McQuade features local heroes in a weekly Heroes Among Us segment. If you would like to nominate someone to be featured on Heroes Among Us, click here to email heroes@wtvr.com.

Read this article:
She overcame 6 brain surgeries and exchanged her hospital gown for scrubs: 'It's my destiny' - wtvr.com

Hanover author urges us to give our brains a workout – Valley News

Think your brain is destined to shrivel bit by bit as the years go by?

Think again, says John Randolph.

In his new book, The Brain Health Book, the Hanover neuropsychologist presents a sunny view of gray matter, making the case that our brains are not only able to withstand the forces of aging but capable of regeneration and even growth later in life.

We really do have a fair amount of control over our brain health, Randolph said in a recent telephone interview. What the science says is that the things that matter the most are the lifestyle choices that are free or inexpensive and available to all of us.

These choices range from intuitive techniques such as doing crossword puzzles and sudoku to strategies less obviously connected to cognition, such as exercising, maintaining social connections and even defining your core values. Randolph, who conducts research at the Geisel School of Medicine at Dartmouth College and has his own practice as a brain health coach and consultant in Lebanon, also emphasizes preventive measures including proper nutrition, adequate sleep and stress management.

If such a regimen sounds a bit overwhelming, Randolph recommends tackling the techniques one at a time. Read just a few chapters and let those chapters simmer a bit, he said. Its important to be realistic. Making even a 10-15% change in one area of your life can make a huge difference.

The book offers a laypersons look at some of the latest research in neuroscience, along with checklists, quizzes and stories from Randolphs practice, where he treats people with cognitive challenges as well as those who are simply interested in improving and preserving their cognitive skills.

Randolph, who is scheduled to discuss his book at the Norwich Bookstore on Wednesday, believes that latter group is beginning to grow.

Its sort of like investing, he said. I think the wave of the future is to be thinking about how our brains are functioning right now and how that plots onto our future even decades down the road.

For that reason, the book may be most relevant not to people in their 70s and 80s although its never too late to think about brain health but to those in their 40s, 50s and 60s. Many of the studies presented in the book demonstrate how lifestyle factors in middle age affect brain function in the later years.

For example, one evidence-based study showed that women who were the most physically fit in middle age were 88% less likely to develop Alzheimers disease or other forms of dementia than women who were moderately fit.

The importance of exercise in maintaining brain health really cannot be overemphasized, Randolph writes. It reduces inflammation, which has been linked to Alzheimers; lowers stress, which affects a variety of cognitive functions; boosts neurochemicals that help us focus, learn and remember new things; and even promotes growth in the hippocampus and frontal cortex.

There is simply no better intervention to date that impacts the brain so profoundly and completely as exercise, he writes.

The book also shows how social connections are closely linked to brain health. The amount of time we spend socializing, the size of our social networks and the degree of support we feel in those networks all play a role in cognition as we age. Conversely, negative relationships and isolation hurt the brain. Studies found that cognitive skills declined 20% faster among people who described themselves as lonely and that particularly isolated people have a 60% higher risk of cognitive decline than people with a large social network.

The book also demonstrates how stimulating mental activities such as playing games, reading and playing instruments improve brain health. One particularly compelling study examined sets of twins in which one played a musical instrument and one didnt. The twins who played instruments were 64% less likely to develop dementia than those who didnt.

Randolph, who moved to the Upper Valley from the West Coast 18 years ago to complete clinical and research fellowships in neuropsychology and neuroimaging at Dartmouth, has applied much of the research to his own life. He tries to eat a mostly Mediterranean-style diet high in whole grains, fish, fruit, vegetables and legumes and stays active by running, playing racquetball, snowboarding, skiing and kayaking. At 48, hes in the prime age bracket to invest in his brain health.

And those investments arent limited to physical concerns like exercise and diet. Randolph also makes the case that our outlook and values have a profound effect on our brains, clearing out mental clutter and sharpening our focus on what matters.

When we have a stronger purpose in life, when we have a good sense of what drives us day to day, that improves how the brain works, he said. Gratitude would be another example. When people engage in gratitude exercises on a regular basis, their brain health tends to be stronger.

John Randolph will be at the Norwich Bookstore on Wednesday at 7 p.m. For information or to save a seat, call 802-649-1114 or email info@norwichbookstore.com.

Sarah Earle can be reached at searle@vnews.com or 603-727-3268.

See the original post:
Hanover author urges us to give our brains a workout - Valley News

Researchers decode the science behind good lighting – News-Medical.net

Researchers at UW Medicine have decoded what makes good lighting - lighting capable of stimulating the cone photoreceptor inputs to specific neurons in the eye that regulate circadian rhythms.

Their study, "A color vision circuit for non-image-forming vision in the primate retina," published in Current Biology Feb. 20, identifies a cell in the retina, which plays an important role in signaling our brain centers that regulate circadian rhythms, boost alertness, help memory and cognitive function, and elevate mood.

These effects have been attributed to a pigment in the eye called melanopsin, which is sensitive to blue light, but researchers say cone photoreceptors are a thousand times more sensitive to light than melanopsin. The cone photoreceptor inputs to the circadian circuity respond to short wavelength blue light, but they also respond strongly to long wavelength oranges and yellows and contrasting light - the colors at sunrise and sunset.

Lead author Sara Patterson, a graduate student in neuroscience at the University of Washington School of Medicine, said how we set our internal clocks to the external light-dark cycle has been studied a lot. But how the changes in the color of light affect our brain has not.

"Color vision used for something other than color perception was the most exciting part for me," she said.

In the study, Patterson and colleagues identified a cell known as an inhibitory interneuron or amacrine cell in the retina, which signals to photosensitive ganglion cells that affect our circadian brain centers. The researchers said these amacrine cells provide "the missing component of an evolutionary ancient color vision circuit capable of setting the circadian clock by encoding the spectral content of light."

Patterson said so little is known about rare retinal circuitry that it was possible to find a new blue cone cell. She said there is a lot more to be discovered about how blue cone cells are projecting to other areas of the brain.

While sunrise lights, blue lights and seasonal affective disorder (SAD) lights have all tried to capture benefits of natural light, they haven't been that effective because they are missing key science data, said corresponding author Jay Neitz, professor of ophthalmology at the UW School of Medicine, a scientist at the UW Medicine Eye Institute, and a well-known color vision researcher. He said the science behind SAD lights, for example, is to make lights hundreds of times brighter than normal lights to stimulate melanopsin.

This research all started because of our interest in the health benefits of having natural light that occurs at the right time of day that helps regulate our circadian clock and our mood and alertness."

Jay Neitz, professor of ophthalmology, UW School of Medicine

The University of Washington has licensed technology based on this discovery to TUO, a lighting technology company that will be selling white LED lightbulbs that will incorporate undetectable sunrise and sunset wavelengths for commercial use.

Source:

Journal reference:

Patterson, S.S., et al. (2020) A Color Vision Circuit for Non-Image-Forming Vision in the Primate Retina. Current Biology. doi.org/10.1016/j.cub.2020.01.040.

View original post here:
Researchers decode the science behind good lighting - News-Medical.net

Brain and Brawn: Hitting the Gym Slows Neurodegeneration in Older People At Risk of Alzheimer’s – Technology Networks

For the first time, an intervention - lifting weights - has been able to slow and even halt degeneration, over a long period, in brain areas particularly vulnerable to Alzheimer's disease.

Researchers have found that six months of strength training (lifting weights) can help protect brain areas especially vulnerable to Alzheimers disease up to one year later.

The team, led by researchers at the University of Sydney, conducted a clinical trial for older people at high risk of Alzheimers disease due to mild cognitive impairment.

Mild cognitive impairment involves a decline in memory and other thinking skills despite generally intact daily living skills, and is one of strongest risk factors for dementia. People with mild cognitive impairment are at a one-in-10 risk of developing dementia within a year.

Study participants were randomly allocated to do computerised brain training, strength training, combined computer and strength training, which they did for just six months followed by their usual activity for 12 months.

The long-term study found that strength training led to overall benefits to cognitive performance, benefits linked to protection from degeneration in specific subregions of the hippocampus. The hippocampus is a complex structure in the brain with a major role in learning and memory.

The hippocampus subregions targeted by the strength training were those especially vulnerable to Alzheimers disease. In the control condition, where no strength training was undertaken hippocampal subregions shrunk by 3-4 percent over the 18-months, whilst those undergoing strength training saw only 1-2 percent reductions, and in some areas, none at all.

The findings have been published this month in the specialist journal Neuroimage: Clinical.

Strength training is a type of physical exercise that requires repetitive contraction of the major muscle groups against an opposing force, typically a free weight or using gym equipment. Participants in this study did supervised strength training for just 90 minutes in total each week, over two or three weekly sessions.

Dr Kathryn Broadhouse, now with the University of the Sunshine Coast, who led the analysis while at the University of Sydney, said the data showed that strength training could exert important biological effects.

Our research shows that strength training can protect some hippocampal subregions from degeneration or shrinkage for up to 12-months after the training has stopped, Dr Broadhouse said.

To arrive at their conclusions, the team conducted MRI brain scans of the participants three times over an 18-month period and used some of the latest advances in image analysis to quantify changes to subregions within the hippocampus, the brains memory hub.

Hippocampal segmentation is difficult because the borders between structures are sometimes unclear and even anatomists will debate where to draw the line, so we restricted our analysis to those subregions where the data is consistent, Dr Broadhouse said.

Professor Michael Valenzuela, leader of the Regenerative Neuroscience Group at the University of Sydneys Brain and Mind Centre and the senior author of the study, believes the finding should change the dementia prevention message.

This is the first time any intervention, medical or lifestyle, has been able to slow and even halt degeneration in brain areas particularly vulnerable to Alzheimers disease over such a long time, said Professor Valenzuela, from the Sydney Medical School in the Faculty of Medicine and Health.

Given this was also linked to protection from cognitive decline, the message is clear: resistance exercise needs to become a standard part of dementia risk-reduction strategies, he said.

Professor Valenzuela is one of the leaders of the multi-million-dollar Australian Maintain your Brain online trial (www.maintainyourbrain.org) that will test if a tailored program of lifestyle modification, including resistance exercise, can prevent cognitive loss in a group of 6,000+ older adults.

Reference: Broadhouse, K. M., Singh, M. F., Suo, C., Gates, N., Wen, W., Brodaty, H., Jain, N., Wilson, G. C., Meiklejohn, J., Singh, N., Baune, B. T., Baker, M., Foroughi, N., Wang, Y., Kochan, N., Ashton, K., Brown, M., Li, Z., Mavros, Y., Valenzuela, M. J. (2020). Hippocampal plasticity underpins long-term cognitive gains from resistance exercise in MCI. NeuroImage: Clinical, 25, 102182. https://doi.org/10.1016/j.nicl.2020.102182

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Brain and Brawn: Hitting the Gym Slows Neurodegeneration in Older People At Risk of Alzheimer's - Technology Networks

First Clinical Evidence of Neuroprotection in Acute Stroke? – Medscape

LOS ANGELES A new potential neuroprotectant agent has been found to be beneficial for patients with acute ischemic stroke undergoing endovascular thrombectomy in a large placebo-controlled trial, but only for those patients who did not also receive thrombolysis.

There was no difference between groups on the primary outcome in the main analysis of the trial, lead author Michael Hill, MD, reported.

However, "In our study, we found a dramatic interaction of nerinetide with alteplase. There was a large benefit of nerinetide in patients not given thrombolysis, but in patients who received alteplase, this benefit was completely obliterated," Hill told Medscape Medical News.

"In patients not treated with thrombolysis, we found a large effect size with a 9.5% absolute improvement in patients having an independent outcome (modified Rankin Score [mRS] 0-2) and a number need to treat of 10 to 11," he said. "We also found a mortality benefit and a reduction in the size of strokes, with all other secondary outcomes going in the right direction.

"The drug works really well in patients who do not get thrombolysis, but it doesn't work at all in patients who have had thrombolysis. The thrombolytic appears to break the peptide down so it is inactive," he added.

"This is the first evidence that neuroprotection is possible in human stroke. This has never been shown before," Hill noted. "Many previous clinical trials of potential neuroprotectants have been negative. We think this is a major breakthrough. This is pretty exciting stuff with really tantalizing results."

Hill, who is professor of neurology at the University of Calgary, Alberta, Canada, presented results of the ESCAPE-NA1 trial today at the International Stroke Conference (ISC) 2020. The trial was also simultaneously published online in the Lancet.

The new agent known as NA1 or nerinetide is a 20 amino acid peptide with a novel mechanism of action; it inhibits signaling that leads to neuronal excitotoxicity. "It reduces endogenous nitric oxide generated inside the cell during ischemia, which is one of the main biochemical processes contributing to cell death," Hill explained. In a primate model of ischemia reperfusion that was published in Nature in 2012, it was highly protective, he added.

The drug is given just once at the time of thrombectomy. It is short lived in the blood but detectable in the brain for up to 24 hours, Hill said.

The trial included 1105 patients who had experienced acute ischemic stroke due to large-vessel occlusion within a 12-hour treatment window and for whom imaging results suitable for thrombectomy were available. The patients were randomly assigned to receive either intravenous nerinetide in a single dose of 2.6 mg/kg or saline placebo at the time of thrombectomy.

Patients were stratified by intravenous alteplase treatment and by declared endovascular device choice.

The primary outcome was a favorable functional outcome 90 days after randomization, defined as an mRS score of 02. In the main analysis of the whole population, this favorable outcome was achieved for 61.4% of the group that received nerinetide and for 59.2% of the placebo group, a nonsignificant difference. Secondary outcomes were also similar between the two groups.

But an exploratory analysis showed evidence that nerinetide's treatment effect was modified by alteplase treatment.

Among the patients who did not receive alteplase, use of nerinetide was associated with improved outcomes, whereas no benefit was found in the alteplase stratum. The difference in absolute risk slightly but not significantly favored placebo.

In the stratum that did not receive alteplase (40% of the trial population), the favorable mRS outcome was achieved by 59.3% of patients who received nerinetide, compared with 49.8% of those given placebo a significant difference (adjusted risk ratio, 1.18; 95% confidence interval, 1.01 1.38).

There was also a 7.5% absolute risk reduction in mortality at 90 days post treatment with nerinetide for the patients who did not receive thrombolysis. This resulted in an approximate halving of the hazard of death (adjusted hazard ratio, 0.56).

In addition, infarct size was reduced in those patients who received nerinetide but not thrombolysis.

Among the patients who received alteplase, the proportion of patients who achieved an mRS of 02 wassimilar between groups, as were median infarct volumes.

The observed treatment effect modification by alteplase was supported by reductions in peak plasma nerinetide concentrations in the alteplase stratum, the researchers report.

They say that the combination of the clinical results in the no-thrombolytic stratum and subsequent tests documenting that nerinetide is broken down by plasmin (which is generated by alteplase) "provide evidence that the clinical observation of effect modification is not a chance finding." But they add: "This novel observation will require additional confirmation, and we cannot draw a definitive conclusion on treatment effect in this study."

There is still more work to do, Hill said. "We don't fully understand the pharmacology, and we will certainly have to do another trial, but we believe this agent is going to shake the field up.

"This is a totally new drug, and we have to think carefully about where it could fit in," he said. "The obvious first group is those patients who do not receive thrombolysis. This is a large group, as most patients do not present in time for thrombolysis. Then we can work on the biochemistry and see if we can develop a version of nerinetide that is resistant to breakdown by thrombolysis."

Another possibility would be to withhold thrombolysis and give nerinetide instead. "It may be that thrombolysis is not needed if patients are receiving thrombectomy this is being suggested now in initial studies," Hill stated.

They also chose a very select group of patients those undergoing thrombectomy, who represent only 10% to 15% of stroke patients. "We have to work out how to expand that population," he said.

Hill noted that there have been many examples in the past of potential neuroprotectantagents that have worked in animal models of ischemia-reperfusion but that failed in humans with acute stroke.

"Until recently, we have not had a reliable ischemia-reperfusion model in humans, but now with endovascular therapy, we have a situation where the blood flow is reliably restored, which is an ideal situation to test new neuroprotectant agents. That may be another factor that has contributed to our positive findings," he said.

In an accompanying comment in the Lancet, Graeme J. Hankey, MD, the University of Western Australia, Perth, notes that although endovascular thrombectomy after use of intravenous alteplase improves reperfusion and clinical outcomes for a fifth of patients with ischemic stroke caused by large-artery occlusion, half of patients do not recover an independent lifestyle. Cytoprotection aims to augment the resilience of neurons, neurovascular units, and white matter during ischemia until perfusion is restored.

Hankey also points out that numerous cytoprotection strategies have been reported to reduce brain infarction in preclinical models of ischemic stroke but have not been found to improve clinical outcomes in clinical trials involving patients with ischemic stroke.

The advent of thrombectomy provides an opportunity to reassess cytoprotection as an adjunctive therapy for patients with types of temporary brain ischemia that align more closely with successful preclinical models of ischemia, cytoprotection, and reperfusion, he adds.

On the results of the current study and the benefit in the no-thrombolysis group, Hankey states: "Although this result might be a chance finding or confounded by the indication for alteplase, complementary pharmacokinetic data in a small number of patients treated with nerinetide showed that alteplase lowered plasma concentrations of nerinetide, probably by converting plasminogen to plasmin, which cleaves peptide bonds not only in fibrin but also in the eicosapeptide nerinetide."

He says the ESCAPE-NA1 trial "informs the study of cytoprotection as an adjunct therapy to reperfusion in acute ischemic stroke" and suggests that researchers who have reported encouraging results of other cytoprotective therapies for ischemic stroke should test their compounds for interactions with concurrent thrombolytic therapies.

The ESCAPE-NA1 trial was sponsored by NoNO, the company developing nerinetide. Hill has received grants from NoNO for the conduct of the study, is named on a US patent for systems and methods for assisting in decision making and triaging for acute stroke patients, and owns stock in Calgary Scientific. Other coauthors are employees of NoNO or have stock options in the company. Hankey has received personal honoraria from the American Heart Association, AC Immune, Bayer, Bristol-Myers Squibb, and Medscape outside the area of work that he commented on.

International Stroke Conference (ISC) 2020: Abstract LB2. Presented February 20, 2020.

Lancet. Published online February 20. Abstract, Comment

For more Medscape Neurology news, join us on Facebook and Twitter.

See the original post:
First Clinical Evidence of Neuroprotection in Acute Stroke? - Medscape

Teacher, 26, died after accidentally taking too many painkillers and being told to make her own way to hospital – Telegraph.co.uk

A young science teacher who dialled 999 after complaining she could barely walk died just hours later after an operator mistakenly advised her to make her own way to A&E, an inquest heard.

Amber Hickford, 26, said she was experiencing dizziness and blurred vision after falling into a bedside cabinet, but her 999 call was "coded" incorrectly on the scale of the emergency and no ambulance was sent to her address.

Instead Miss Hickford was advised to take herself to hospital, which involved navigating two flights of stairs. But she refused to go despite being offered help by her boyfriend, Jason Hanmer.

Miss Hickford tried to sleep it off, but when Mr Hanmer found her unresponsive in bed around 99 minutes later, he called 999 again. He began CPR while an ambulance was dispatched to their apartment in Rochdale, Greater Manchester.

Three ambulances arrived at the property within 10 minutes of Mr Hanmer's call being made but Miss Hickford was pronounced dead shortly afterwards. Tests showed she had inadvertently taken a toxic level of paracetamol for severe stomach pains she had been experiencing following a urinary infection.

Inquiries revealed she had been discharged from hospital just two days earlier and given stronger codeine painkillers. The call handler who fielded Miss Hickford's 999 call has since been given "feedback" over the error.

The inquest was told Miss Hickford, who taught at Oulder Hill Community School in Rochdale, had been "extremely caring" and "always put other people's needs before her own". After attaining a 2:1 in biochemistry at Leeds University, she passed her teaching exams and undertook voluntary work for Barnado's children's charity.

The tragic events began on April 19 last year after Miss Hickford was admitted to Fairfield Hospital in Bury with stomach problems. Doctors gave her codeine and sent her home, with advice to attend a follow-up appointment. But on April 21, she rang the NHS 111 service at around 8.40pm saying she was struggling to walk.

Mr Hanmer told the inquest in Heywood: "As I got home Amber was sat in the hallway, and she said she was feeling drowsy. I made her tea, but later that evening she fell into a shoe cabinet and into the bedside table.

"She couldn't walk at all and went drowsy every time she stood up. I could tell she was very unsteady. I rang 111, and the operator said they would not to talk to me and asked to speak to Amber herself.

"They told her to ring 999, but when she rang, the call handler told her to go to A&E. We live up two flights of stairs and I couldn't get her down safely by myself. Her parents arrived but Amber stated that she didn't want to go to the hospital and her parents left.

"I went out to move my car and went straight back to the bedroom and Amber was in there making snoring noises.

"I moved her on to her side and was only gone again 10 minutes before I went back to check on her. I shouted out but didn't get a response and rushed over to her, and she was cold. I listened to see but she wasn't breathing.

"I pulled her on to the floor and called 999, and they talked me through CPR. The paramedics arrived and then came into the room but said Amber wasn't breathing and her heart had stopped and machines were doing it for her. They called another ambulance for help getting her downstairs. Amber passed away later in hospital. We had been together for two years."

Miss Hickford's father, Neil, said: "She had mentioned that she did have some stomach pains but she had just started a new job and felt some of that might be down to nerves.

"At around 9pm that evening, Jay rang saying they had called the emergency services and asked us to help him convince Amber to go to hospital as she wasn't listening to him.

"When we got there, Amber was standing and dressed but still didn't want to go to hospital. We stayed there until around 10pm, and we were almost home and Jay phoned again around 10.20pm saying he had rung the ambulance and wanted us to go back. There were three ambulances outside, and the paramedics were working on Amber on the floor in the bedroom. It was devastating to be told she could not be resuscitated.

"Amber was a science teacher and would be aware of the nature of the medication she was taking and the effects that may have. She would never have knowingly taken more than she should have."

Angela Lee, Deputy Sector Manager for the North West Ambulance Service, said: "On April 21, an emergency call was received, and although Amber's abdominal pain seemed to have subsided, she was now struggling to walk and experiencing dizziness, drowsiness and blurred vision when stood.

"At 10.24pm - around two hours later - a further call was received from Amber and three emergency response vehicles were allocated.

"The initial emergency call was coded a category four but should have been coded as a category two response. When I listened to the emergency call, I didn't hear anything that gave me cause for concern that it was coded correctly, but if the call had been categorised as a category two, there may have been an emergency ambulance to attend to Amber.

"The call handler who handled the call has received feedback, which revolved around a one-to-one session."

When questioned by Amber's family about why the callhandler had not dispatched an ambulance following the first 999 call, Ms Lee said: "They have a couple of seconds to make that decision and it's a very difficult task. The call was passed to a clinician who spoke to Jay and then to Amber and the clinician gave the advice to attend the emergency department."

Coroner Michael Salt adjourned the hearing for further inquiries but said: "I accept that the call was coded incorrectly. I need to know more about the potential effect of the delay in the arrival of the ambulance and what could have been achieved in the time - that seems to me at least an hour and 36 minutes.

"I have heard about the way in which the categorisation error came about in a very difficult situation. A judgement needs to be made very quickly, and I don't in any way criticise the call taker.

"The question is whether something could have been achieved in the time that might have been available. The important thing is to try to find out whether the delay contributed to death and whether it was a missed opportunity."

Read the rest here:
Teacher, 26, died after accidentally taking too many painkillers and being told to make her own way to hospital - Telegraph.co.uk